Vagifem
Vagifem is an ultra-low-dose estradiol vaginal tablet FDA-approved for vaginal dryness and dyspareunia in menopause, with minimal systemic absorption.
How it works
Vagifem delivers 10 micrograms of estradiol — an ultra-low dose — directly to vaginal tissue with minimal systemic absorption. The low absorption means serum estradiol levels remain in the postmenopausal range even with regular use, which is the basis for its use in breast cancer survivors and others for whom systemic estrogen is contraindicated (though this should be confirmed with each patient's oncologist). It is inserted with a single-use disposable applicator. The dosing schedule is typically daily for an initial two-week loading period, then twice weekly for maintenance. Symptom improvement — particularly tissue moisture, elasticity, and reduction in dyspareunia — generally develops over four to twelve weeks.
Like all vaginal estrogen, Vagifem targets the genitourinary syndrome of menopause: vaginal dryness, thinning, painful intercourse, and related urinary symptoms. A progestogen is not required for uterine protection because systemic absorption is minimal, though this should be confirmed with a physician in individual cases.
How to track Vagifem
- Vaginal dryness or discomfort level — the primary symptom target; rate on a consistent scale from week one.
- Dyspareunia (painful intercourse) if applicable — track frequency and severity separately from general dryness.
- Insertion comfort — the applicator insertion process itself can be uncomfortable initially as tissue is atrophic; tracking this separately shows whether tissue is improving.
- Application schedule adherence — initial daily loading vs. twice-weekly maintenance are different phases; logging which phase you are in clarifies the expected trajectory.
- Urinary urgency, frequency, or recurrent UTIs — vaginal estrogen often improves urinary symptoms as local tissue is restored.
- Rate vaginal dryness from day one of treatment, not just when you expect to see improvement — the baseline and early-weeks data show the rate of tissue response.
- Track insertion comfort as a separate item from dryness symptoms — it is a distinct marker of tissue condition and often improves before systemic dryness symptoms resolve.
- Note whether you are in the loading phase (daily) or maintenance phase (twice weekly) in your log — response expectations differ by phase.
- Log any spotting or discharge in the first few weeks separately — some light spotting is not unusual as estrogen-sensitive tissue responds to treatment, but a log helps distinguish normal from concerning.
- If you are also being treated for a hormone-sensitive cancer, log when you discussed Vagifem use with your oncologist and the date — that conversation should be documented.
Questions to ask your physician
- My vaginal dryness rating was [X] before starting Vagifem. At [N] weeks, my current rating is [Y]. Is that pace of improvement typical for ultra-low-dose vaginal estradiol?
- I've been tracking dyspareunia — it has [improved/not improved] after [N] weeks. Does that suggest the current formulation or dose is appropriate, or should we consider a different option?
- I finished the two-week daily loading phase [date] and moved to twice-weekly maintenance. My symptom log shows [pattern]. Is the maintenance schedule appropriate, or do I need to adjust?
- I've been logging urinary urgency alongside vaginal symptoms — the pattern shows [result]. Is the urinary improvement consistent with what's expected from vaginal estradiol at this timeframe?